+34 679 490 537info@nanbiosis.com

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@ub.edu
  • Scientific Coordinator: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
Order request

This Unit is coordinated by the Peptides and Nanoparticles Group at the Parc Científic de Barcelona (PCB) and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the PCB with an occupy area of 5.000m2.

Active projects

TitleFundin: OrganismCall: Funding source Role
ICTS-2017-10-CIBER-2Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperimentMinisterio de Economía, Industria y Competitividad (MINECO)Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)Coordinator
GA: 720942SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-FabryUnión Europea (Comisión Europea)H2020-NMBP-2016-2017Coordinator
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Other projects

RefTitleFunding OrganismUnit Role
SAF2015-67476-RImmunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS)Ministerio de Economía y CompetitividadParticipant
RTC-2014-2207-1TERARMET: Development of therapies for the treatment of rare congenital metabolic diseasesMINECOParticipant



  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

22 Oct

Researchers of NANBIOSIS U3 working in a project to develop molecules with neutralizing properties of SARS-CoV-2

The research group of Chemical Multivalent Systems for Nanomedicine and NANBIOSIS U3 Sinthesys of Peptides Unit, of IQAC-CSIC and CIBER-BBN, participates in a new project that seeks to develop molecules with neutralizing properties of SARS-CoV-2, the cause of the COVID-19 disease, for the treatment of patients requiring hospitalization and clinical supervision due to the severity of the infection. The project, led by the Public University of Navarra (UPNA) and Navarrabiomed, counts with the participation of researchers from institute of advanced chemistry of catalonia (Institute of Advanced Chemistry of Catalonia), IRB Barcelona (Institute for Biomedical Research), CIBER-BBN (Center for Networked Biomedica[...]

21 Sep

NANBIOSIS Expertise in the IQAC-CSIC Symposium dedicated to the fight against Covid-19 Pandemic

The 4th Annual IQAC Symposium will take place on September 23, 2020. This year will be dedicated to the research projects on COVID-19 that are being carried out in the IQAC-CSIC. It will be a dissemination day aiming to inform the general public about some of the lines of research that are currently being developed in the fight against the COVID-19 pandemic. The event will be live streamed in Facebook: facebook.com/iqac.csic.es/ Three of the speakers, members of CIBER-BBN NANBIOSIS units at IQAC-CSIC, will explain their work. Pilar Marco and Roger Galve (NANBIOSIS U2 Custom Antibody Service (CAbS) will talk about[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

27 May

Peptide‐Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate.

Osteoporosis is an illness which appears when the osteoblast/osteoclast activities are unbalanced taking place bone resorption (caused by osteoclasts) in higher extension than bone formation (induced by osteoblasts). Alendronate is one of the most used drugs for osteoporosis treatment despite its scarce bioavailability. In an attempt to improve it, gated mesoporous silica nanoparticles, for the controlled release of alendronate, have been synthesized and characterized. These hybrid nanoparticles include labelled alendronate inside the porous, those porous are capped with a peptide designed to be selectively cleaved by cathepsin K enzyme (overexpressed in osteoclasts). Two CIBER-BBN units of the ICTS NANBIOSIS wer[...]

16 Apr

A new strategy to synthesize Chol-PEG “on demand”

Researchers of NANBIOSIS U3 Synthesis of Peptides Unit of CIBER-BBN at IQAC-CSIC, led by Miriam Royo, have published an article in the scientific journal ACS Omega that develops a method for the production of cholesterol conjugates to peptide ligands through polyethylene glycol (ND-PEG) not dispersed through a non-hydrolyzable bond. The developed methodology allows to generate stable, highly pure and well defined Chol-PEG compounds, linked to different lengths of PEG from 4 to 20 units of ethylene oxide through an ether bond. These Chol-PEG compounds were conjugated with different peptides, such as cyclic peptide (RGDfK), gluturation and a Tf1R peptide ligand,[...]

09 Apr

NANBIOSIS U2, U3 & U29 participate in the POC4CoV project to develop diagnostic technologies for SARS-COV-2

The Spanish Higher Council for Scientific Research (CSIC) will finance the project Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV), whose objective is to have effective diagnostic technologies for Covid-19. The Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and the Institute of Materials Science of Aragon (ICMA) participate in it. The POC4CoV project aims to develop Point-of-Care (POC) devices for the in vitro diagnosis of SARS-COV-2 infection quickly and reliably, thanks to the use of multiplexed systems and the use of particular biomolecular probes. To do this, POC technological platforms will b[...]

27 Feb

Rare diseases Day February 29: combating Fabry Disease

29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February. NanoMed Spain Platform and the Hospital of Sant Joan de Déu have organized the NanoRareDiseaseDay to present the latest innovations in the field of Nanomedicine for the treatment and diagnosis of rare diseases (diseases affecting less than 5 people per 10,000 inhabitants). Nora Ventosa, Scientific Director of NANBIOSIS U6 Biomaterial Processing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]